Vanguard Group Inc. Grows Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL)

Vanguard Group Inc. boosted its holdings in shares of Nuvalent, Inc. ( NASDAQ:NUVL – Free Report ) by 8.

9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,499,864 shares of the company’s stock after purchasing an additional 366,239 shares during the period. Vanguard Group Inc.



owned about 6.33% of Nuvalent worth $352,249,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds also recently added to or reduced their stakes in the business.

KLP Kapitalforvaltning AS acquired a new stake in Nuvalent in the 4th quarter valued at $595,000. American Century Companies Inc. acquired a new position in Nuvalent during the fourth quarter worth about $14,590,000.

Teacher Retirement System of Texas grew its holdings in Nuvalent by 43.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,609 shares of the company’s stock valued at $830,000 after buying an additional 3,197 shares in the last quarter.

Cibc World Markets Corp purchased a new stake in shares of Nuvalent in the 4th quarter valued at approximately $257,000. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Nuvalent by 13.4% during the 4th quarter.

Commonwealth Equity Services LLC now owns 2,618 shares of the company’s stock worth $205,000 after purchasing an additional 309 shares during the period. 97.26% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Nuvalent In other news, CFO Alexandra Balcom sold 4,016 shares of Nuvalent stock in a transaction on Monday, January 6th. The stock was sold at an average price of $79.68, for a total value of $319,994.

88. Following the completion of the sale, the chief financial officer now owns 61,734 shares of the company’s stock, valued at $4,918,965.12.

The trade was a 6.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website .

Also, CEO James Richard Porter sold 27,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $75.87, for a total transaction of $2,048,490.

00. Following the transaction, the chief executive officer now directly owns 249,062 shares of the company’s stock, valued at approximately $18,896,333.94.

This represents a 9.78 % decrease in their position. The disclosure for this sale can be found here .

Over the last 90 days, insiders have sold 108,800 shares of company stock valued at $8,437,464. Insiders own 12.52% of the company’s stock.

Nuvalent Stock Down 3.0 % Nuvalent ( NASDAQ:NUVL – Get Free Report ) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($1.

05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02).

Analysts expect that Nuvalent, Inc. will post -3.86 EPS for the current year.

Wall Street Analysts Forecast Growth Several analysts recently weighed in on NUVL shares. HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Nuvalent in a report on Monday, March 3rd.

UBS Group raised shares of Nuvalent from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research report on Friday, March 14th. Finally, Wedbush reissued an “outperform” rating and set a $115.

00 price objective on shares of Nuvalent in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $113.

44. View Our Latest Stock Analysis on Nuvalent About Nuvalent ( Free Report ) Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

Further Reading Want to see what other hedge funds are holding NUVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvalent, Inc. ( NASDAQ:NUVL – Free Report ).

Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter ..